ONCODESIGN
ALONC | PA
Overview
Corporate Details
- ISIN(s):
- FR0011766229
- LEI:
- 9695004HPDBVG72O8851
- Country:
- France
- Address:
- 20 RUE JEAN MAZEN, 21000 DIJON
- Website:
- https://www.oncodesign.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Founded in 1995 by Dr Philippe Genne, the Company’s CEO and Chairman, Oncodesign is a biopharma company dedicated to the precision medicine. With its unique experience acquired by working with more than 600 clients, including the world’s largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2022-12-13 14:25 |
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
|
French | 150.7 KB | |
2022-12-13 11:17 |
Regulatory News Service
Franchissement de seuils
|
French | 209.0 KB | |
2022-11-24 08:00 |
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
|
French | 145.1 KB | |
2022-11-23 17:37 |
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
|
French | 724.9 KB | |
2022-11-23 17:36 |
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
|
French | 2.3 MB | |
2022-11-08 16:38 |
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
|
French | 2.2 MB | |
2022-11-08 15:54 |
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
|
French | 231.6 KB | |
2022-11-02 17:28 |
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
|
French | 1.0 MB | |
2022-11-02 17:25 |
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
|
French | 506.0 KB | |
2022-10-26 11:17 |
Regulatory News Service
Franchissement de seuil
|
French | 198.3 KB | |
2022-10-26 11:16 |
Regulatory News Service
Franchissement de seuils
|
French | 206.0 KB | |
2022-10-19 08:00 |
Inside Information Statement
Inside Information / Operations of the issuer (acquisitions, sales...)
|
English | 340.5 KB | |
2022-10-19 08:00 |
Inside Information Statement
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
|
French | 390.8 KB | |
2022-10-04 18:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 268.6 KB | |
2022-10-04 18:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 273.9 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
1NKEMIA | Spain | IKM | |
![]() |
2cureX AB | Sweden | 2CUREX | |
![]() |
4SC AG | Germany | VSC | |
![]() |
Abera Bioscience AB | Sweden | ABERA | |
![]() |
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
![]() |
AB Science | France | AB | |
![]() |
Acticor Biotech | France | ALACT | |
![]() |
Active Biotech | Sweden | ACTI | |
![]() |
AcuCort AB | Sweden | ACUC |